» Articles » PMID: 16166585

Pathology of Berkeley Sickle Cell Mice: Similarities and Differences with Human Sickle Cell Disease

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2005 Sep 17
PMID 16166585
Citations 92
Authors
Affiliations
Soon will be listed here.
Abstract

Because Berkeley sickle cell mice are used as an animal model for human sickle cell disease, we investigated the progression of the histopathology in these animals over 6 months and compared these findings to those published in humans with sickle cell disease. The murine study groups were composed of wild-type mixed C57Bl/6-SV129 (control) mice and sickle cell (SS) mice (alpha-/-, beta-/-, transgene +) of both sexes and between 1 and 6 months of age. SS mice were similar to humans with sickle cell disease in having erythrocytic sickling, vascular ectasia, intravascular hemolysis, exuberant hematopoiesis, cardiomegaly, glomerulosclerosis, visceral congestion, hemorrhages, multiorgan infarcts, pyknotic neurons, and progressive siderosis. Cerebral perfusion studies demonstrated increased blood-brain barrier permeability in SS mice. SS mice differed from humans with sickle cell disease in having splenomegaly, splenic hematopoiesis, more severe hepatic infarcts, less severe pulmonary manifestations, no significant vascular intimal hyperplasia, and only a trend toward vascular medial hypertrophy. Early retinal degeneration caused by a homozygous mutation (rd1) independent from that causing sickle hemoglobin was an incidental finding in some Berkeley mice. While our study reinforces the fundamental strength of this model, the notable differences warrant careful consideration when drawing parallels to human sickle cell disease.

Citing Articles

Targeting sickle cell pathobiology and pain with novel transdermal curcumin.

Goel Y, Arellano M, Fouda R, Garcia N, Lomeli R, Kerr D PNAS Nexus. 2025; 4(2):pgaf053.

PMID: 40007577 PMC: 11854080. DOI: 10.1093/pnasnexus/pgaf053.


Metabolic and Proteomic Divergence is Present in Spleens and Livers from Berkeley Sickle Cell Anemia and β-Thalassemia Mice.

Rana N, Lisk C, Cendali F, Lucero M, Grier A, Setua S J Proteome Res. 2025; 24(3):1306-1316.

PMID: 39947632 PMC: 11895773. DOI: 10.1021/acs.jproteome.4c00814.


Targeting P-selectin and interleukin-1β in mice with sickle cell disease: effects on vaso-occlusion, liver injury and organ iron deposition.

Gotardo E, Torres L, Zaidan B, Gushiken L, Brito P, Leonardo F Haematologica. 2024; 110(3):725-738.

PMID: 39568425 PMC: 11873698. DOI: 10.3324/haematol.2024.286418.


Simvastatin-Mediated Nrf2 Activation Induces Fetal Hemoglobin and Antioxidant Enzyme Expression to Ameliorate the Phenotype of Sickle Cell Disease.

Xi C, Palani C, Takezaki M, Shi H, Horuzsko A, Pace B Antioxidants (Basel). 2024; 13(3).

PMID: 38539870 PMC: 10968127. DOI: 10.3390/antiox13030337.


Cardiovascular consequences of sickle cell disease.

Palomarez A, Jha M, Medina Romero X, Horton R Biophys Rev (Melville). 2024; 3(3):031302.

PMID: 38505276 PMC: 10903381. DOI: 10.1063/5.0094650.


References
1.
PITCOCK J, MUIRHEAD E, HATCH F, Johnson J, Kelly B . Early renal changes in sickle cell anemia. Arch Pathol. 1970; 90(5):403-10. View

2.
Vichinsky E, Styles L, Colangelo L, Wright E, Castro O, Nickerson B . Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood. 1997; 89(5):1787-92. View

3.
Stockman J, Nigro M, Mishkin M, Oski F . Occlusion of large cerebral vessels in sickle-cell anemia. N Engl J Med. 1972; 287(17):846-9. DOI: 10.1056/NEJM197210262871703. View

4.
Romayanada N, Goldberg M, Green W . Histopathology of sickle cell retinopathy. Trans Am Acad Ophthalmol Otolaryngol. 1973; 77(5):OP652-76. View

5.
Asdourian G, Nagpal K, Goldbaum M, Patrianakos D, Goldberg M, Rabb M . Evolution of the retinal black sunburst in sickling haemoglobinopathies. Br J Ophthalmol. 1975; 59(12):710-6. PMC: 1017440. DOI: 10.1136/bjo.59.12.710. View